Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Switching to Long-Acting Cabotegravir Plus Rilpirivine for HIV Treatment: Assessing Candidacy and Patient Counseling

This podcast episode features an international panel discussion on the nuts and bolts of switching patients to long-acting injectable cabotegravir plus rilpivirine for HIV treatment.
person default
Yvonne Gilleece, MB BCh, BAO
Cristina Mussini, MD
Babafemi Taiwo, MBBS
Darrell H. S. Tan, MD, FRCPC, PhD
Released: July 14, 2022

In this episode, an international expert panel shares their thoughts on key steps for switching patients to long-acting injectable cabotegravir plus rilpivirine for HIV treatment, including selecting the most appropriate patients, introducing patients to the long-acting option, and preparing patients for what to expect from long-acting treatment in terms of efficacy, visit timing, and the injection experience. Subsequent episodes in this 4-part series will cover additional aspects of long-acting antiretrovirals for HIV treatment and prevention, including operational planning, clinic impact, and handling missed doses with long-acting antiretroviral therapy for treatment; long-acting HIV pre-exposure prophylaxis; and what is still needed in long-acting HIV care to further address patient needs and inequities across subgroups.

Information on this Educational Activity

Faculty

Yvonne Gilleece, MB BCh, BAO

Honorary Clinical Professor in HIV Medicine and Sexual Health
Department of Global Health & HIV
Brighton & Sussex Medical School
Consultant in HIV Medicine and Sexual Health
HIV Department
University Hospitals Sussex NHS Foundation Trust
Brighton, United Kingdom

Yvonne Gilleece, MB, BCh, BAO, has disclosed that she has received payment for educational meetings from ViiV, advisory board fees from Gilead Sciences and ViiV, and conference sponsorship from Gilead Sciences.
Cristina Mussini, MD

Head of Department of Infectious Diseases and Tropical Medicine
Full Professor of Infectious Diseases

Infectious Diseases Clinics, University Hospital
University of Modena and Reggio Emilia
Modena, Italy

Cristina Mussini, MD, has disclosed that she has received consulting fees from AbbVie, Angelini, Gilead Sciences, Janssen, MSD, and ViiV Healthcare and funds for research support from Gilead Sciences, Janssen, MSD, and ViiV Healthcare.
Babafemi Taiwo, MBBS

Gene Stollerman Professor of Medicine
Chief,
Division of Infectious Diseases
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Babafemi Taiwo, MBBS, has disclosed that he has received consultant/advisor/speaker fees from Gilead Sciences, Merck, and ViiV Healthcare/GSK and funds for independent contractor from Johnson & Johnson.
Darrell H. S. Tan, MD, FRCPC, PhD

Associate Professor
Division of Infectious Diseases
University of Toronto
Clinician-Scientist
Division of Infectious Diseases
St. Michael's Hospital
Toronto, Canada

Darrell H. S. Tan, MD, FRCPC, PhD, has disclosed that he has received funds for research support from AbbVie, Gilead Sciences, and GlaxoSmithKline.

Program Medium

This program has been made available online.

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
ViiV Healthcare

Related Content

Listen to Drs Jill Blumenthal and Jennifer Cocohoba discuss ART tolerability in transgender persons and the many factors to consider, from Clinical Care Options (CCO)

Jill Blumenthal, MD, MAS Jennifer Cocohoba Headshot Jennifer Cocohoba, PharmD Released: December 7, 2022

Discussion of barriers and calls to action for providing patient-centered HIV care in Malaysia from a healthcare professional and a patient advocate, from Clinical Care Options (CCO)

person default Iskandar Azwa, MBChB Andrew Tan Released: December 7, 2022

Dr Sylvia Ojoo discusses data on cryptococcal meningitis in people with HIV from the fall 2022 HIV conferences, from Clinical Care Options (CCO)

person default Sylvia Ojoo, CCST (UK), MRCP (UK), DTM&H (UK), DFFP (UK), MBChB Released: December 6, 2022

Clinical Care Options (CCO) expert audio: Drs Chloe Orkin and Babafemi Taiwo discuss new HIV data presented at IDWeek and HIV Glasgow 2022

Chloe Orkin Photo Chloe Orkin, MBChB, FRCP, MD Babafemi Taiwo, MBBS Released: December 5, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings